Poseltinib
Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly. Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Poseltinib
Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly. Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.
has abstract
Poseltinib (HM71224, LY3337641 ...... ther immunological conditions.
@en
CAS number
1353552-97-2
FDA UNII code
D01E4B1U35
PubChem
Wikipage page ID
52,971,323
page length (characters) of wiki page
Wikipage revision ID
1,015,354,385
Link from a Wikipage to another Wikipage
CAS number
IUPAC name
N-acrylamide
@en
PubChem
56,644,522
SMILES
C=CC=O
@en
synonyms
HM-7122; LY 3337641
@en
UNII
D01E4B1U35
@en
wikiPageUsesTemplate
comment
Poseltinib (HM71224, LY3337641 ...... ther immunological conditions.
@en
label
Poseltinib
@en